Analysts predict that Viking Therapeutics Inc (NASDAQ:VKTX) will post ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Viking Therapeutics reported earnings per share of ($0.11) during the same quarter last year, which suggests a negative year-over-year growth rate of 18.2%. The company is expected to issue its next quarterly earnings results on Wednesday, November 6th.
According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.61) to ($0.40). For the next financial year, analysts forecast that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.96) to ($0.47). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02).
A number of analysts recently issued reports on VKTX shares. ValuEngine raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Viking Therapeutics in a research report on Friday, August 2nd. BidaskClub cut Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 6th. Stifel Nicolaus started coverage on Viking Therapeutics in a research report on Tuesday, June 25th. They set a “buy” rating and a $14.00 price objective for the company. Finally, Oppenheimer started coverage on Viking Therapeutics in a research report on Tuesday, July 16th. They set an “outperform” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the company. Viking Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.53.
Several large investors have recently made changes to their positions in the business. BlackRock Inc. grew its position in shares of Viking Therapeutics by 22.4% during the fourth quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock worth $31,361,000 after buying an additional 749,505 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Viking Therapeutics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after purchasing an additional 1,555 shares during the last quarter. Northern Trust Corp lifted its stake in Viking Therapeutics by 18.5% during the fourth quarter. Northern Trust Corp now owns 728,958 shares of the biotechnology company’s stock worth $5,576,000 after purchasing an additional 113,995 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Viking Therapeutics during the fourth quarter worth approximately $1,478,000. Finally, Stifel Financial Corp lifted its stake in Viking Therapeutics by 30.7% during the fourth quarter. Stifel Financial Corp now owns 22,314 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 5,237 shares during the last quarter. 62.91% of the stock is owned by institutional investors.
Shares of VKTX stock traded down $0.20 on Friday, reaching $6.83. 11,380 shares of the company’s stock traded hands, compared to its average volume of 2,445,925. Viking Therapeutics has a 12-month low of $6.68 and a 12-month high of $24.00. The company has a market capitalization of $507.64 million, a P/E ratio of -17.12 and a beta of 2.29. The company has a 50 day moving average of $7.90.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.
Recommended Story: What is a blue-chip stock?
Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.